Literature DB >> 29263193

Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes.

Milton Packer1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29263193     DOI： 10.2337/dci17-0052

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  22 in total

1.  Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.

Authors:  Mathilde Fraty; Gilberto Velho; Elise Gand; Fréderic Fumeron; Stéphanie Ragot; Philippe Sosner; Kamel Mohammedi; Barnabas Gellen; Pierre-Jean Saulnier; Jean-Michel Halimi; David Montaigne; Grégory Ducrocq; Michaela Rehman; Michel Marre; Ronan Roussel; Samy Hadjadj
Journal:  Diabetologia       Date:  2018-09-19       Impact factor: 10.122

Review 2.  Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.

Authors:  Javed Butler; Milton Packer; Stephen J Greene; Mona Fiuzat; Stefan D Anker; Kevin J Anstrom; Peter E Carson; Lauren B Cooper; Gregg C Fonarow; Adrian F Hernandez; James L Januzzi; Mariell Jessup; Rita R Kalyani; Sanjay Kaul; Mikhail Kosiborod; JoAnn Lindenfeld; Darren K McGuire; Marc S Sabatine; Scott D Solomon; John R Teerlink; Muthiah Vaduganathan; Clyde W Yancy; Norman Stockbridge; Christopher M O'Connor
Journal:  Circulation       Date:  2019-12-16       Impact factor: 29.690

Review 3.  Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?

Authors:  Rosalie A Scholtes; Michaël J B van Baar; Yuliya Lytvyn; Petter Bjornstad; Max Nieuwdorp; David Z I Cherney; Daniël H van Raalte
Journal:  Diabetes Obes Metab       Date:  2019-04       Impact factor: 6.577

4.  Stopping Empagliflozin Unmasks Heart Failure.

Authors:  Morolake Amole; Julio Leey-Casella
Journal:  Fed Pract       Date:  2021-11

5.  The mitochondria-targeted antioxidant MitoQ ameliorates myocardial ischemia-reperfusion injury by enhancing PINK1/Parkin-mediated mitophagy in type 2 diabetic rats.

Authors:  Yelong Ji; Yan Leng; Shaoqing Lei; Zhen Qiu; Hao Ming; Yi Zhang; Aining Zhang; Yang Wu; Zhongyaun Xia
Journal:  Cell Stress Chaperones       Date:  2022-04-15       Impact factor: 3.827

Review 6.  Implications of the Intestinal Microbiota in Diagnosing the Progression of Diabetes and the Presence of Cardiovascular Complications.

Authors:  Alina Mihaela Leustean; Manuela Ciocoiu; Anca Sava; Claudia Florida Costea; Mariana Floria; Claudia Cristina Tarniceriu; Daniela Maria Tanase
Journal:  J Diabetes Res       Date:  2018-11-12       Impact factor: 4.011

Review 7.  Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers.

Authors:  Filippos Triposkiadis; Andrew Xanthopoulos; John Parissis; Javed Butler; Dimitrios Farmakis
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

8.  Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.

Authors:  Jagdeep S S Singh; Ify R Mordi; Keeran Vickneson; Amir Fathi; Peter T Donnan; Mohapradeep Mohan; Anna Maria J Choy; Stephen Gandy; Jacob George; Faisel Khan; Ewan R Pearson; J Graeme Houston; Allan D Struthers; Chim C Lang
Journal:  Diabetes Care       Date:  2020-04-03       Impact factor: 19.112

9.  Novel ASK1 inhibitor AGI-1067 improves AGE-induced cardiac dysfunction by inhibiting MKKs/p38 MAPK and NF-κB apoptotic signaling.

Authors:  Zhongwei Liu; Shixiang Zheng; Xi Wang; Chuan Qiu; Yan Guo
Journal:  FEBS Open Bio       Date:  2018-08-17       Impact factor: 2.693

10.  ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus.

Authors:  Cheng Liu; Yanfang Li; Tianwang Guan; Yanxian Lai; Yan Shen; Abudurexiti Zeyaweiding; Haiyan Zhao; Fang Li; Tutiguli Maimaiti
Journal:  Cardiovasc Diabetol       Date:  2018-09-18       Impact factor: 9.951
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.